IMMUNOTHERAPY IN NSCLC : FROM TARGETED MOLECULES TO RESISTANCE PATTERNS - Université de Reims Champagne-Ardenne Access content directly
Journal Articles Pharmacogenomics Journal Year : 2020

IMMUNOTHERAPY IN NSCLC : FROM TARGETED MOLECULES TO RESISTANCE PATTERNS

Abstract

Immunotherapies are now considered as a pillar of non-small-cell lung cancer treatment. The main targets of immune-checkpoint inhibitors (ICI) are programmed cell death 1/programmed cell death ligand 1 and cytotoxic T-lymphocyte antigen 4, aiming at restoring antitumor immunity. Despite durable responses observed in some patients, all patients do not benefit from the treatment and almost all responders ultimately relapse after some time. In this review, we discuss the biomarkers that could be used to predict response to ICI, the current indications of ICI in non-small-cell lung cancer, the mechanisms inducing tumor-cell intrinsic or extrinsic resistance to ICI and finally, the potential treatment response monitoring.

Dates and versions

hal-02933087 , version 1 (08-09-2020)

Identifiers

Cite

Sylvie Brassart-Pasco, Véronique Dalstein, Bertrand Brassart, Maxime Dewolf, Christine Clavel, et al.. IMMUNOTHERAPY IN NSCLC : FROM TARGETED MOLECULES TO RESISTANCE PATTERNS. Pharmacogenomics Journal, 2020, 21 (10), pp.705-720. ⟨10.2217/pgs-2020-0021⟩. ⟨hal-02933087⟩
22 View
0 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More